Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

L-lysine/L-arginine-containing amino acid solution

An intravenous (IV) amino acid (AA) solution containing the cationic amino acids L-lysine and L-arginine, with radioprotective activity. Upon IV administration of the AA solution, L-lysine and L-arginine are specifically taken up by the kidneys. This protects the kidneys from toxicity by certain co-administered radio-labeled peptides as they compete with radio-labeled peptides for renal uptake. This reduces uptake of the radio-labeled peptides by the kidneys and decreases their renal retention. It also increases the target-to-kidney ratio of the radio-labeled peptides, thereby reducing radiation exposure to the kidneys and preventing nephrotoxicity.
Synonym:amino acid renal protectant solution
amino acid solution-containing L-lysine and L-arginine
intravenous L-lysine/L-arginine-containing amino acid solution
L-lysine/L-arginine AA solution
radioprotective amino acid solution
Search NCI's Drug Dictionary